Rona Yaeger, MD

Rona Yaeger, MD, details the efficacy of adagrasib/cetuximab in heavily pretreated patients with KRAS G12C–mutant mCRC.

Rona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.